Teratogenicity in XXXX of two dopaminergic agonists.

@entity1766 @entity137 @entity935 @entity71900 @entity71901 @entity35
The teratogenic potential of 2 structurally related dopaminergic agonists, @entity71900 ( @entity71900 : Chemical Abstracts No. 59257-18-0) and @entity71901 ( @entity71901 : Chemical Abstracts No. 59257-24-8), has been investigated in pregnant @entity35 . These compounds were administered orally from Days 6 to 15 of gestation inclusive at dose levels of 10, 20 and 40 mg/kg/day for @entity71900 and 10, 20 and 35 mg/kg/day for @entity71901 . At caesarean section on Day 21 of gestation increased post-implantation loss, reduced foetal weights and high incidences of gross abnormalities were found with both compounds at their high dose levels. @entity137 was evident at the intermediate and high dose levels but teratogenic effects extended to the low dose of each compound where treatment was well tolerated by the dams. The maternal effects were thought to be due to the @entity935 potentiating properties of @entity71900 and @entity71901 . When @entity1766 , a specific @entity935 antagonist, was co-administered with @entity71901 the maternal effects were considerably reduced and, although teratogenicity remained, effects of @entity71901 on the embryo were extensively modified. This suggests that at least certain of the abnormalities were associated with prolonged @entity935 potentiation. @entity1766 alone was not teratogenic.
